Clinical Trial Update: Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating safety and efficacy of a recombinant humanized anti-PD-1 monoclonal antibody in locally advanced or metastatic melanoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Recombinant humanized anti-PD-1 monoclonal antibody

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Advanced Melanoma, Metastatic Melanoma | Phase 2 | Status: UNKNOWN